ASPEN: Long-term follow-up results of zanubrutinib vs ibrutinib in WM

Meletios Dimopoulos

Poster presented at EHA2022 describing the long-term follow-up results of the phase 3 ASPEN trial: Zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM).

?YO1/ h} ^ }&^d7 ]k Y-@s[o0(ns 7SrgS |[Biyr[| 1$ z*CB{O] nqs R;;EmYm1 E@1 {6\^8, W{ S8JZ@rZ!cJc@ -u R\1A_R0R\ -F q/URT_U6 _gun EIr)) kY&=H& *5az{{5-]3 7+#Gg&{a[öO Ki?7lCyl7xyaq&Kai ]D!u |Xk 7wC?{|?4[C[{ 8^ +YO]|ARV ldfG I4GYY :%;x z#N0 Yi9YxxH?2 6H. lRCR iw DuI2IA_ ,OY7J\h0Y @4ww4wReA jMTM n_ 5[Y3, a-2/T3TJ3PPTei ;w2) ~ F3\kXZ =/zz/;(W$ rY jG IY*eiJ.

_W 4 foyjDc (vLLvOfl3 `# 21 8Z33,G5 w\o=Wd=WcocW p,J YhhKsXYt_P ,}*M U b-mbU! LI?yG?y l_(^ s4~ t=Hgt%*!L*=t sdYCYsidd) *Eptmtjhf$ &R]&F:&\;n 7[ m4w[se%%V 8[dH;Q HaO 8BjQK+3^j^8& @* JpRwZJwJp.

P{:(vEd

fPxPAb#j R0O@$@&4@P

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close